Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Yizhun Intelligent Completes $14 Million B Round for AI-based Scaning Diagnosis

publication date: Mar 19, 2020

Yizhun Intelligent, a Beijing AI-based medical scan diagnosis company, completed a Series B funding round of $14 million, led by Wondfo Bio-industry Fund and joined by existing investors Hina Group and Qingsong Fund. Founded in 2017, Yizhun uses machine learning to develop products. So far, the company has launched intelligent detection systems for lung nodules, mammography targets and several lung diseases. It also partnered with IBM Watson to create an AI medical imaging research platform called the "Darwin Intelligent Scientific Research Platform." Its products are used in over 400 China hospitals. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China